The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Carmat SAS is the designer and developer of the world’s most advanced artificial heart. Carmat is an innovative medtech company created and financed by Truffle Capital, EADS and the Fondation Alain Carpentier, with additional funding from the French state innovation agency OSEO.
Carmat’s aim is to be able to provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.
Following a first round of financing led by Truffle Capital in 2008, Carmat was listed on the Alternext market in July 2010, thus raising 15.5m€. Truffle Capital is Carmat’s first shareholder.
The first heart implantation was performed in December 2013, at the Georges Pompidou hospital in Paris.
Truffle Capital board member: Dr. Philippe Pouletty
L’intervention de Marcello Conviti, Directeur Général de Carmat, lors de la 2e édition du Truffle Exchange organisé le 20 mars 2012.
Interview de Marcello Conviti, Directeur Général de Carmat, lors de la deuxième édition de Truffle Exchange, quand la bourse rencontre l’innovation, le 20 mars 2012